This proposal extends our previous transplantation studies with blastula- derived embryonic stem (ES) cells by comparing the morphological development and functional effects of this potentially optimal source of donor cells for transplantation with that of fetal ventral mesencephalic (VM) cells. The propagation of ES cells in culture can produce an almost unlimited supply of untransformed, totipotent cells that can be used for neural transplantation. We have previously shown that implementation of blastula-derived ES cells into the brain results in heterogeneous grafts containing cells of neuronal morphology and expressing neuronal markers characteristic of dopaminergic (DA) neurons (e.g. tyrosine hydroxylase positive and dopamine-beta hydroxylase negative). In addition, when placed into the DA-denervated striatum in a PD rat model, these cells selectively extended axonal processes into appropriate regions of the host brain. These studies utilized large bolus transplants (200,000 cells) and in some cases produced undifferentiated and non-neuronal cells. The proposed studies will systematically explore the effects of graft size (injected cell number and concentration) and of graft sites on the development of ES cells into DA neuronal phenotypes, and to determine their functional effects in two animal models of PD. By comparing the efficacy of ES cell grafts versus fetal VM cell grafts to ameliorate behavioral symptoms of DA cell loss, in both rodent and primate hosts, we can assess the potential of ES cells to serve as a cell source for transplantation therapies in Parkinson's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
3P50NS039793-03S1
Application #
6499659
Study Section
Special Emphasis Panel (ZNS1)
Project Start
2001-08-01
Project End
2002-07-31
Budget Start
Budget End
Support Year
3
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Mc Lean Hospital (Belmont, MA)
Department
Type
DUNS #
City
Belmont
State
MA
Country
United States
Zip Code
02478
Wang, Xin; Li, Nuomin; Xiong, Nian et al. (2017) Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson's Disease. Mol Neurobiol 54:2878-2888
Xiong, Nian; Li, Nuomin; Martin, Eden et al. (2016) hVMAT2: A Target of Individualized Medication for Parkinson's Disease. Neurotherapeutics 13:623-34
Hallett, Penelope J; Deleidi, Michela; Astradsson, Arnar et al. (2015) Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell 16:269-74
Hallett, Penelope J; Cooper, Oliver; Sadi, Damaso et al. (2014) Long-term health of dopaminergic neuron transplants in Parkinson's disease patients. Cell Rep 7:1755-61
McLean, Jesse R; Hallett, Penelope J; Cooper, Oliver et al. (2012) Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol Cell Neurosci 49:230-9
Deleidi, Michela; Isacson, Ole (2012) Viral and inflammatory triggers of neurodegenerative diseases. Sci Transl Med 4:121ps3
Lindvall, Olle; Barker, Roger A; Brüstle, Oliver et al. (2012) Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell 10:151-5
Cooper, Oliver; Hallett, Penny; Isacson, Ole (2012) Using stem cells and iPS cells to discover new treatments for Parkinson's disease. Parkinsonism Relat Disord 18 Suppl 1:S14-6
Hallett, Penelope J; McLean, Jesse R; Kartunen, Andrew et al. (2012) ýý-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiol Dis 47:258-67
Deleidi, Michela; Cooper, Oliver; Hargus, Gunnar et al. (2011) Oct4-induced reprogramming is required for adult brain neural stem cell differentiation into midbrain dopaminergic neurons. PLoS One 6:e19926

Showing the most recent 10 out of 91 publications